Application of effective parts of astragalus mongholicus and hedysarum polybotrys

Abstract

The invention belongs to the traditional Chinese medicine field and relates to the preparation of effective parts of astragalus mongholicus and hedysarum polybotrys and selection thereof for pulmonary fibrosis model intervention so as to obtain further study on the effective parts having the optimal curative effect. An interstitial pulmonary fibrosis model of rats is established through modeling; and compared with the normal rats, the rats having interstitial pulmonary fibrosis have obvious difference and pathologic change typical cases in various related detection indexes and pathologic changes. The various effective parts of astragalus mongholicus and hedysarum polybotrys are capable of suppressing various related indexes of the interstitial pulmonary fibrosis model of rats induced by bleomycin and preventing the development of interstitial pulmonary fibrosis, wherein low and medium dose groups of hedysarum polybotrys flavone have the optimal effect. The degree of the effect of the effective parts of astragalus mongholicus and hedysarum polybotrys on stopping the progress of interstitial pulmonary fibrosis is related to appropriate concentrations of equivalent dugs. Through comprehensive assessment, the hedysarum polybotrys flavone is better in influence on the lung function, HA, LN, HYP and the like of the rats having interstitial pulmonary fibrosis than other effective parts.

Description

technical field [0001] The invention relates to the application of a traditional Chinese medicine extract, in particular to the application of the effective parts of astragalus and red qi. Background technique [0002] Pulmonary fibrosis, that is, the interstitial tissue of the lung is composed of collagen, elastin, and protein sugars. When fibroblasts are chemically or physically injured, they will secrete collagen to repair the interstitial tissue of the lung, resulting in pulmonary fibrosis. Transformation; that is, after the lungs are injured, the result of the body's repair. [0003] Pulmonary fibrosis usually occurs between the ages of 40 and 50, and it occurs more frequently in men than in women. Dyspnea is the most common symptom of pulmonary fibrosis. In mild pulmonary fibrosis, dyspnea occurs only with strenuous activity and is therefore often overlooked or misdiagnosed as another disorder. When pulmonary fibrosis progresses, dyspnea also occurs at rest, and pat...

AI Technical Summary

Problems solved by technology

[0004] At present, the method of treating pulmonary fibrosis is generally western medicine treatment, such as glucocorticoids (prednisone is also called prednisone), immunosuppressants or cytotoxic drugs (cyclophosphamide, azathioprine), antioxidants ( Ambromide, taurine), anti-fibrotic drugs (pirfenidone, IT_ receptor antagonists, monoclonal antibodies,), receptor inhibitors (leukotriene receptor antagonists, tumor necrosis factor-α Inhibitors, flower growth factor-β inhibitors), immunomodulators (BCG polysaccharide nucleic acid, levamisole), other drugs (colchicine, macrolide antibiotics, interferon-γ, angiotensin conversion Enzyme inhibitors) and gene therapy methods, etc., traditional Chinese medicine treatment is still relatively rare

Images